Centessa Pharmaceuticals plc Overview
Pro stress-test →Centessa Pharmaceuticals is a UK-based clinical-stage pharmaceutical company focused on discovering and developing transformational medicines. The company's primary focus is on orexin receptor 2 (OX2R) agonists for sleep-wake disorders and other neurological conditions, with its lead program ORX750 in Phase 2a development.
Strategic Profile
Pro stress-test →Centessa leverages a differentiated orexin agonist platform with multiple programs targeting significant unmet medical needs in sleep disorders, neurodegeneration, and neuropsychiatric conditions. The company also maintains an immuno-oncology program via its LockBody technology platform, providing pipeline diversification beyond its core orexin focus.
Competitive Landscape
Pro stress-test →Centessa competes in the sleep disorder and neuropsychiatric pharmaceuticals space against larger biotech firms and specialized neurology companies developing similar symptom-targeting therapies. The company's orexin agonist approach differentiates it from traditional monoamine-based treatments, positioning it in an emerging category with limited direct competitors at similar clinical stages.
Industry Context
Centessa Pharmaceuticals plc operates in Clinical-stage Pharmaceutical/Biotech - Neurology Focus.
Key facts
Founded: 2020 · Headquarters: Altrincham, UK